Laura D. Locati

List of Publications by Year
in descending order

161	6,171	93792	90395
papers	citations	39 h-index	73 g-index

165	165	165	7566
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60â€‰mg Per Day Compared with the Cabozantinib Capsule at 140â€‰mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid, 2022, 32, 515-524.	2.4	9
2	Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.. Journal of Clinical Oncology, 2022, 40, 9520-9520.	0.8	5
3	Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series. Tumori, 2021, 107, 030089162095284.	0.6	4
4	Management of loco-regionally advanced squamous laryngeal cancer in elderly patients. European Archives of Oto-Rhino-Laryngology, 2021, 278, 771-779.	0.8	3
5	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. Acta OncolÃ³gica, 2021, 60, 1192-1200.	0.8	13
6	Malignant salivary gland tumours in families with breast cancer susceptibility. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 221-226.	1.4	0
7	A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy of AqualiefTM Mucoadhesive Tablets in Head and Neck Cancer Patients Who Developed Radiation-Induced Xerostomia. Cancers, 2021, 13, 3456.	1.7	3
8	Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients. Cancers, 2021, 13, 3983.	1.7	1
9	An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma. JCO Precision Oncology, 2021, 5, 1526-1527.	1.5	1
10	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptorâ€“Expressing Salivary Gland Cancer: A Phase II Trial. Journal of Clinical Oncology, 2021, 39, 4061-4068.	0.8	24
11	Head and Neck Cancers. UNIPA Springer Series, 2021, , 707-729.	0.1	0
12	Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirusâ€“Positive Oropharyngeal Carcinoma. JCO Precision Oncology, 2021, 5, 1666-1676.	1.5	6
13	Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. Frontiers in Oncology, 2021, 11, 799453.	1.3	5
14	Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.5	3
15	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. Seminars in Cancer Biology, 2020, 60, 344-350.	4.3	26
16	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. Laryngoscope, 2020, 130, 857-865.	1.1	25
17	Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. Frontiers in Oncology, 2020, 10, 518110.	1.3	9
18	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. Cancers, 2020, 12, 2958.	1.7	29

#	Article	IF	Citations
19	A monocentric, open-label randomized standard-of-care controlled study of XONRIDÂ®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients. Radiation Oncology, 2020, 15, 193.	1.2	9
20	Quality of Life in Patients With Hypoparathyroidism After Treatment for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4652-e4660.	1.8	33
21	Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era. Cancers, 2020, 12, 3769.	1.7	2
22	Managing locally advanced adenoid cystic carcinoma of the head and neck during the COVID-19 pandemic crisis: Is this the right time for particle therapy?. Oral Oncology, 2020, 106, 104803.	0.8	8
23	Major and minor salivary gland tumours. Critical Reviews in Oncology/Hematology, 2020, 152, 102959.	2.0	44
24	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. European Journal of Cancer, 2020, 136, 35-42.	1.3	27
25	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer, 2020, 126, 1888-1894.	2.0	54
26	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 922.	1.7	12
27	Rare thyroid malignancies in Europe: Data from the information network on rare cancers in Europe (RARECAREnet). Oral Oncology, 2020, 108, 104766.	0.8	5
28	Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. European Journal of Cancer, 2019, 118, 35-40.	1.3	70
29	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Followâ€up. Otolaryngology - Head and Neck Surgery, 2019, 161, 635-642.	1.1	26
30	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. Cancers, 2019, 11, 1057.	1.7	25
31	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head and Neck, 2019, 41, 3670-3676.	0.9	29
32	Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study. Oral Oncology, 2019, 97, 99-104.	0.8	3
33	Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review. Critical Reviews in Oncology/Hematology, 2019, 143, 67-75.	2.0	21
34	Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 1856-1883.	0.6	592
35	Systemic Therapy in Salivary Gland Carcinoma. , 2019, , 213-224.		0
36	PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. Oncology, 2019, 97, 112-118.	0.9	1

#	Article	IF	Citations
37	Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. PLoS ONE, 2019, 14, e0213934.	1.1	7
38	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. Expert Opinion on Investigational Drugs, 2019, 28, 435-443.	1.9	8
39	Adjuvant androgen deprivation therapy for poor-risk, androgen receptorâ€“positive salivary duct carcinoma. European Journal of Cancer, 2019, 110, 62-70.	1.3	46
40	The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment. Tumori, 2019, 105, NP28-NP31.	0.6	2
41	Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. Future Oncology, 2019, 15, 2543-2553.	1.1	10
42	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. Head and Neck, 2019, 41, 1895-1902.	0.9	10
43	Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2019, 37, 6029-6029.	0.8	2
44	Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.. Journal of Clinical Oncology, 2019, 37, e17530-e17530.	0.8	3
45	Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocrine-Related Cancer, 2019, 26, 241-250.	1.6	20
46	Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. Drugs in Context, 2019, 8, 1-6.	1.0	7
47	Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients.. Journal of Clinical Oncology, 2019, 37, e17537-e17537.	0.8	0
48	Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 379-385.	1.5	27
49	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1217-1221.	0.4	9
50	Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. Targeted Oncology, 2018, 13, 253-256.	1.7	11
51	Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. Endocrine-Related Cancer, 2018, 25, 217-231.	1.6	50
52	Prognostic role of PIK3CA and TP53 in human papillomavirusâ€“negative oropharyngeal cancers. Tumori, 2018, 104, 213-220.	0.6	4
53	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treatment Reviews, 2018, 65, 78-86.	3.4	32
54	In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating. Human Pathology, 2018, 74, 32-42.	1.1	15

#	Article	IF	Citations
55	Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study. European Journal of Cancer, 2018, 104, 219-223.	1.3	8
56	In Reply to Fakhry etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 102, 670-671.	0.4	1
57	Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells. Annals of Oncology, 2018, 29, 1599-1601.	0.6	12
58	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. European Journal of Cancer, 2018, 97, 7-15.	1.3	34
59	A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.. Journal of Clinical Oncology, 2018, 36, 6021-6021.	0.8	7
60	Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract (NCT02860936).. Journal of Clinical Oncology, 2018, 36, 6086-6086.	0.8	7
61	Druggable molecular targets in skin adnexal malignancies.. Journal of Clinical Oncology, 2018, 36, e21619-e21619.	0.8	0
62	Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).. Journal of Clinical Oncology, 2018, 36, TPS6099-TPS6099.	0.8	0
63	Lung metastasectomy in adenoid cystic cancer: Is it worth it?. Oral Oncology, 2017, 65, 114-118.	0.8	68
64	Immunohistochemical and molecular profile of salivary gland cancer in children. Pediatric Blood and Cancer, 2017, 64, e26468.	0.8	14
65	Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. Oral Oncology, 2017, 66, 58-63.	0.8	90
66	The EORTC module for quality of life in patients with thyroid cancer: phase III. Endocrine-Related Cancer, 2017, 24, 197-207.	1.6	34
67	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncology, 2017, 69, 33-37.	0.8	16
68	Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 349-361.	2.2	65
69	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 2017, 28, 2820-2826.	0.6	66
70	PD-034: Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer. Radiotherapy and Oncology, 2017, 122, 20.	0.3	0
71	Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding. Annals of Oncology, 2017, 28, 2321-2322.	0.6	9
72	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. Genes, 2017, 8, 35.	1.0	27

#	Article	IF	Citations
73	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. Disease Markers, 2017, 2017, 1-9.	0.6	4
74	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. Journal of Clinical Oncology, 2017, 35, 9543-9543.	0.8	5
75	Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. Oncotarget, 2017, 8, 47780-47789.	0.8	32
76	RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?. Oncotarget, 2017, 8, 96184-96189.	0.8	4
77	Safety of Combination Treatment with Imatinib Mesylate, Carboplatin, and Cetuximab in a Patient with Multiple Cancers: A Case Report. Tumori, 2016, 102, S1-S2.	0.6	1
78	Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. Annals of Oncology, 2016, 27, iv110.	0.6	0
79	Temporal course and predictive factors of analgesic opioid requirement for chemoradiationâ€induced oral mucositis in oropharyngeal cancer. Head and Neck, 2016, 38, E1521-7.	0.9	25
80	Health careâ€“associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. Head and Neck, 2016, 38, E1009-13.	0.9	6
81	Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study. Thyroid, 2016, 26, 1605-1613.	2.4	41
82	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 959-966.	0.4	48
83	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. European Journal of Cancer, 2016, 69, 158-165.	1.3	66
84	Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. European Thyroid Journal, 2016, 5, 187-194.	1.2	11
85	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clinical Cancer Research, 2016, 22, 3961-3970.	3.2	65
86	Occupation and cancer of the larynx: a systematic review and meta-analysis. European Archives of Oto-Rhino-Laryngology, 2016, 273, 9-20.	0.8	31
87	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptorâ€positive salivary gland cancers. Head and Neck, 2016, 38, 724-731.	0.9	104
88	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. Oral Oncology, 2016, 54, 54-57.	0.8	46
89	Management of Salivary Gland Cancer. , 2016, , 625-640.		0
90	2827 Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer. European Journal of Cancer, 2015, 51, S567.	1.3	1

#	Article	IF	Citations
91	2865 Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis. European Journal of Cancer, 2015, 51, S578.	1.3	3
92	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2015, 44, 734-745.	1.4	8
93	Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?. Journal of Oral Pathology and Medicine, 2015, 44, 728-733.	1.4	3
94	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Letters, 2015, 359, 269-274.	3.2	9
95	Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials.. Journal of Clinical Oncology, 2015, 33, 6062-6062.	0.8	1
96	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget, 2015, 6, 9627-9642.	0.8	103
97	Detecting characteristics of nodal invasion in advanced squamocellular oral cavity cancer through a gene expression profile on primary tumor.. Journal of Clinical Oncology, 2015, 33, e17069-e17069.	0.8	0
98	Upregulation of RAS pathway to predict the risk of distant metastases in HPV + oropharynx cancer.. Journal of Clinical Oncology, 2015, 33, e17073-e17073.	0.8	0
99	Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area.. Journal of Clinical Oncology, 2015, 33, e17054-e17054.	0.8	0
100	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. Future Oncology, 2014, 10, 2111-2120.	1.1	3
101	Fosbretabulin for the treatment of anaplastic thyroid cancer. Future Oncology, 2014, 10, 2015-2021.	1.1	15
102	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biology and Therapy, 2014, 15, 678-682.	1.5	24
103	Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. Annals of Oncology, 2014, 25, 1628-1635.	0.6	45
104	Antiangiogenic TKIs and Advanced RAI-Resistant Thyroid Cancer: Time for Rethinking Treatment Strategies?. Thyroid, 2014, 24, 1815-1815.	2.4	3
105	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Annals of Oncology, 2014, 25, 462-466.	0.6	83
106	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. Oral Oncology, 2014, 50, 884-887.	0.8	20
107	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. Annals of Oncology, 2014, 25, 694-699.	0.6	33
108	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and qualityâ€ofâ€life assessments. Cancer, 2014, 120, 2694-2703.	2.0	106

#	Article	IF	Citations
109	Safety and feasibility of everyâ€otherâ€week maintenance cetuximab after firstâ€line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head and Neck, 2013, 35, 1471-1474.	0.9	18
110	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. Oral Oncology, 2013, 49, 413-419.	0.8	39
111	RET inhibition: implications in cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 403-419.	1.5	40
112	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. Future Oncology, 2013, 9, 103-114.	1.1	28
113	Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opinion on Emerging Drugs, 2013, 18, 445-459.	1.0	7
114	Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer. Current Opinion in Oncology, 2013, 25, 224-228.	1.1	29
115	Salivary Gland Cancer: An Update on Present and Emerging Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 257-263.	1.8	22
116	Salivary Gland Cancer: An Update on Present and Emerging Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 257-263.	1.8	34
117	Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.. Journal of Clinical Oncology, 2013, 31, 6027-6027.	0.8	2
118	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Annals of Oncology, 2012, 23, 435-441.	0.6	55
119	How Many Therapeutic Options Are There for Recurrent or Metastatic Salivary Duct Carcinoma?. Journal of Clinical Oncology, 2012, 30, 672-672.	0.8	4
120	Palifermin in Prevention of Head and Neck Cancer Radiation-Induced Mucositis: Not Yet a Definitive Word on Safety and Efficacy Profile. Journal of Clinical Oncology, 2012, 30, 564-565.	0.8	18
121	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Annals of Oncology, 2012, 23, 1832-1837.	0.6	97
122	Management of salivary gland tumors. Expert Review of Anticancer Therapy, 2012, 12, 1161-1168.	1.1	60
123	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2012, 67, e226-e228.	0.6	7
124	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Annals of Oncology, 2011, 22, 1886-1893.	0.6	24
125	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. Annals of Oncology, 2011, 22, 2495-2500.	0.6	31
126	Management of Salivary Gland Cancer. , 2011, , 521-532.		0

#	Article	IF	Citations
127	Comment on â€œAcute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysisâ€, by Rades et coll.. Oral Oncology, 2010, 46, 888.	0.8	0
128	Major and minor salivary gland tumors. Critical Reviews in Oncology/Hematology, 2010, 74, 134-148.	2.0	387
129	TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma. Journal of Clinical Oncology, 2010, 28, 761-766.	0.8	104
130	Multikinase inhibitors in thyroid cancer. European Journal of Cancer, 2010, 46, 1012-1018.	1.3	14
131	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology, 2009, 27, 3794-3801.	0.8	337
132	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncology, 2009, 45, 574-578.	0.8	184
133	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncology, 2009, 45, 986-990.	0.8	144
134	Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1053-1059.	0.4	39
135	High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiotherapy and Oncology, 2009, 90, 166-171.	0.3	144
136	8506 Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience. European Journal of Cancer, Supplement, 2009, 7, 472.	2.2	6
137	TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. Translational Oncology, 2008, 1, 121-128.	1.7	15
138	Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). European Journal of Cancer, 2008, 44, 2542-2545.	1.3	63
139	Folate in Head and Neck Squamous Cell Cancer Chemoprevention: Purposely Left Out?. Journal of Clinical Oncology, 2008, 26, 3463-3463.	0.8	2
140	Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. Annals of Oncology, 2008, 19, vii200-vii203.	0.6	18
141	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Annals of Oncology, 2007, 18, 601-602.	0.6	26
142	Biological agents in head and neck cancer. Expert Review of Anticancer Therapy, 2007, 7, 1643-1650.	1.1	4
143	Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2006, 12, 6643-6651.	3.2	159
144	A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?. Current Opinion in Oncology, 2006, 18, 253-257.	1.1	24

#	Article	IF	Citations
145	Advances in the changing patterns of aetiology of head and neck cancers. Current Opinion in Otolaryngology and Head and Neck Surgery, 2006, 14, 95-99.	0.8	7
146	Biological agents in head and neck cancer. Annals of Oncology, 2006, 17, x45-x48.	0.6	3
147	High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 5630-5636.	0.8	605
148	HerceptinÂ® plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncology, 2005, 41, 97-98.	0.8	23
149	Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncology, 2005, 41, 890-894.	0.8	58
150	Which classification for ethmoid malignant tumors involving the anterior skull base?. Head and Neck, 2005, 27, 224-231.	0.9	19
151	Is Restoring Platinum Sensitivity the Best Goal for Cetuximab in Recurrent/Metastatic Nasopharyngeal Cancer?. Journal of Clinical Oncology, 2005, 23, 7757-7758.	0.8	7
152	Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?. Oral Oncology, 2005, 41, 219-221.	0.7	0
153	Cisplatin and Fluorouracil Concurrent to Radiotherapy in Nasopharyngeal Cancer: Is the Schedule Compatible?. Journal of Clinical Oncology, 2004, 22, 377-377.	0.8	1
154	Prediction of TP53 Status for Primary Cisplatin, Fluorouracil, and Leucovorin Chemotherapy in Ethmoid Sinus Intestinal-Type Adenocarcinoma. Journal of Clinical Oncology, 2004, 22, 4901-4906.	0.8	99
155	Head and neck tumors other than squamous cell carcinoma. Current Opinion in Oncology, 2004, 16, 236-241.	1.1	18
156	Cancer of the larynx. Critical Reviews in Oncology/Hematology, 2003, 47, 65-80.	2.0	98
157	A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Annals of Oncology, 2003, 14, 1327-1328.	0.6	55
158	Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Annals of Oncology, 2003, 14, 367-372.	0.6	55
159	Primary high-grade mucoepidermoid carcinoma of the minor salivary glands with cutaneous metastases at diagnosis. Oral Oncology, 2002, 38, 401-404.	0.8	15
160	Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer, 2001, 34, 279-287.	0.9	109
161	How can we address the challenge of distant metastases in HNSCC prognosis?. Expert Review of Anticancer Therapy, 0, , 1-3.	1.1	1